Pembrolizumab + Trastuzumab + FLOT
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophagogastric Adenocarcinoma
Conditions
Esophagogastric Adenocarcinoma
Trial Timeline
Feb 13, 2023 → Dec 1, 2027
NCT ID
NCT05504720About Pembrolizumab + Trastuzumab + FLOT
Pembrolizumab + Trastuzumab + FLOT is a phase 2 stage product being developed by Merck for Esophagogastric Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05504720. Target conditions include Esophagogastric Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05504720 | Phase 2 | Active |
Competing Products
6 competing products in Esophagogastric Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO | Daiichi Sankyo | Phase 1/2 | 41 |
| bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib | Roche | Phase 2/3 | 65 |
| Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo | Amgen | Phase 1/2 | 40 |
| Sacituzumab govitecan | Gilead Sciences | Phase 1/2 | 40 |
| regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin | Bristol Myers Squibb | Phase 2 | 51 |
| 18F-BMS-986229 Injection + IV 18F-BMS-986229 | Bristol Myers Squibb | Pre-clinical | 22 |